Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with TPF Induction for Hypopharyngeal SCC
NCT04624308Phase 2Not yet recruiting
- Start
- Oct 2020
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in hypopharyngeal squamous cell carcinoma (HSCC). Primary endpoint: Complete Remission Rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT04624308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624308.